TheStreet.com -- Reported by Adam Feuerstein in Boston. Follow Adam Feuerstein on Twitter.
TheStreet's biotech columnist offers his own report card on biotech stocks.
A look back at the year's worth of Adam Feuerstein's biotech tweets.
Gilead Sciences is nearing the completion of two phase III studies of the Jak inhibitor momelotinib in myelofibrosis, a disease affecting bone marrow.
Stocks with insider trader activity include LPNT, PATK and CTIC
Stocks with insider trader activity include SPTN, FL and CTIC